INT54234

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1993
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 7
Disease Relevance 2.14
Pain Relevance 1.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Cd2) protein complex (Cd2)
Anatomy Link Frequency
effector T cells 2
immune cell 1
pore 1
Cd2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
tetrodotoxin 8 99.76 Very High Very High Very High
Action potential 10 99.66 Very High Very High Very High
ischemia 53 98.80 Very High Very High Very High
repetitive firing 1 98.12 Very High Very High Very High
qutenza 144 93.88 High High
metalloproteinase 20 92.96 High High
cerebral cortex 8 81.68 Quite High
Inflammation 15 81.36 Quite High
headache 2 68.00 Quite High
pruritus 2 61.28 Quite High
Disease Link Frequency Relevance Heat
Psoriasis 4 99.44 Very High Very High Very High
Cv Unclassified Under Development 86 98.80 Very High Very High Very High
Injury 44 84.28 Quite High
INFLAMMATION 17 81.36 Quite High
Ganglion Cysts 14 71.32 Quite High
Headache 2 68.00 Quite High
Nasopharyngitis 2 67.20 Quite High
Rhinitis 2 65.84 Quite High
Influenza Virus Infection 2 65.04 Quite High
Death 2 64.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Action potentials were completely eliminated with Cd2+ and TTX present.
Cd2 Binding (eliminated) of associated with tetrodotoxin and action potential
1) Confidence 0.35 Published 1993 Journal J. Neurophysiol. Section Abstract Doc Link 7904302 Disease Relevance 0 Pain Relevance 0.56
We suggest that this is probably due to Cd2+ entry through TRPV1 and subsequent binding of Cd2+ to Fura-2.
Cd2 Binding (binding) of
2) Confidence 0.27 Published 2009 Journal Pflugers Arch Section Body Doc Link PMC2765625 Disease Relevance 0.06 Pain Relevance 0.49
We suggest that this is probably due to Cd2+ entry through TRPV1 and subsequent binding of Cd2+ to Fura-2.
Cd2 Binding (binding) of
3) Confidence 0.27 Published 2009 Journal Pflugers Arch Section Body Doc Link PMC2765625 Disease Relevance 0.06 Pain Relevance 0.49
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation and proliferation of memory effector T cells by binding to CD2 expressed on the T cell surface.
CD2 Binding (binding) of in effector T cells associated with psoriasis
4) Confidence 0.26 Published 2005 Journal Expert Opin Drug Saf Section Abstract Doc Link 16255657 Disease Relevance 0.78 Pain Relevance 0.10
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation and proliferation of memory effector T cells by binding to CD2 expressed on the T cell surface.
CD2 Binding (interaction) of in effector T cells associated with psoriasis
5) Confidence 0.26 Published 2005 Journal Expert Opin Drug Saf Section Abstract Doc Link 16255657 Disease Relevance 0.60 Pain Relevance 0.09
However, when combined, Cd2+ and low Ca2+ dramatically reduced signaling (P < 0.005), which is consistent with competition between Ca2+ and Cd2+ for a high affinity pore binding site (Lansman et al., 1986; Chow, 1991; Yang et al., 1993; Ellinor et al., 1995).
Cd2 Binding (competition) of in pore
6) Confidence 0.14 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2592819 Disease Relevance 0.07 Pain Relevance 0
Immunohistochemistry was performed on sections from untreated and vehicle-treated animals that were exposed to H-I (N = 5 per group) to assess the immune cell response using anti-OX-42, an antibody that binds the CD11b antigen that is expressed on cell surfaces of microglia and macrophages.
anti-OX-42 Binding (binds) of in immune cell associated with ischemia
7) Confidence 0.01 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2527306 Disease Relevance 0.57 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox